secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-284564
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted
--------------------------------------------------------------------------------

- Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.
- R&D expenses $8.3M (Q3 2022) vs $1.8M (Q3 2021) due to clinical trial ramp.
- INTERCEPT-AD enrollment expected to complete Q1 2023; topline data anticipated H2 2023.
- FDA granted Fast Track designation for ACU193 in early Alzheimer's in October 2022.
- Appointed Derek Meisner as Chief Legal Officer in September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/0001193125-22-284564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/d410427d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-284564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer